Infographic of randomized controlled trial data on the relationship between adherence and efficacy.
Topic(s): Research
Product(s): Oral PrEP, Trial Prep Options
Format(s): Infographic
Source(s): CAPRISA
Type: Document
These clinical guidelines, developed by Kenya’s Ministry of Health in 2026, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR).
Last update: April 2026 Visit data.prepwatch.org for a dynamic map-based tool to explore trends in PrEP use globally, including by country, product, and time period. Comprehensive datasets are available to download by clicking “download data” in the upper righthand corner. For any questions, contact [email protected]. Introduction to the Global PrEP Tracker
This website, developed and maintained by the University of Liverpool, provides clear, trustworthy, and up-to-date information about how different PrEP options, including oral PrEP, cabotegravir, lenacapavir, and the dapivirine vaginal ring, can interact with other drugs.
These materials, developed by Zambia’s Ministry of Health, can be used to train clinicians and mobilisers in delivery of PrEP methods, including injectable lenacapavir (LEN), cabotegravir (CAB), the dapivirine vaginal ring (DVR), the Dual Prevention Pill (DPP), and oral PrEP.
These clinical guidelines, developed by Zambia’s Ministry of Health in 2025, can be used to support delivery of both PrEP and PEP, including newer, long-acting options such as injectable lenacapavir (LEN), cabotegravir (CAB), and the dapivirine vaginal ring (DVR), as well as the Dual Prevention Pill and oral PrEP.
The HIV Prevention Ambassador Training Package and Toolkit was created to prepare potential and current PrEP users to be leaders – or “Ambassadors” – in the rollout of PrEP for HIV prevention in their communities. Through interactive activities, discussion, and action planning, the training prepares Ambassadors to share information with their peers about PrEP methods…
This suite of clinical reporting forms, developed by South Africa’s National Department of Health, can be used for PrEP reporting, including injectable lenacapavir (LEN). The download folder includes forms for PrEP initiation, continuation, pregnancy outcome reporting, and seroconversion reporting.
These country profiles provide concise, actionable snapshots of the HIV prevention and treatment landscape for key populations across multiple countries, including: Brazil, Eswatini, France, Kenya, Malawi, Mozambique, Nigeria, the Philippines, South Africa, Uganda, Ukraine, the United States, Vietnam, Zambia, and Zimbabwe. Country profiles highlight: History of PrEP introduction Updates on PrEP Products Key population epidemiology…
AVAC’s Country Planning for Product Introduction Matrix tracks key indicators for the introduction of new PrEP products, including lenacapavir (LEN), cabotegravir (CAB), and the Dapivirine Vaginal Ring (DVR), by country, including regulatory status, late stage clinical trials and implementation research, procurement plans, and recent oral PrEP provision.
These clinical guidelines, released by the Ukraine Ministry of Health in 2025, include the latest recommendations for HIV services, including oral PrEP and injectable cabotegravir (CAB) for PrEP.
